Should you register?

A new category of federal registration, created specifically for operators holding a state medical marijuana license.

Before April 28, 2026, there was no federal registration pathway for a cannabis business. The DEA didn't have a box for you. The April 23 order created one — Section 1301.13(k) — and the DEA opened the application portal on April 29.

Your OMMA license is the foundation. The application uses it as conclusive proof that your state has authorized your activity. The DEA is then required to grant the federal registration unless there's a specific public-interest reason to refuse.

The registration is what gives you federal-law cover to operate as a Schedule III business. Everything the rescheduling opens up — banking access, federal commerce relationships, federal frameworks as they develop — flows through it.

Any entity holding an OMMA license that plans to keep manufacturing, distributing, or dispensing under federal Schedule III.

That means dispensaries, processors, growers, and transporters. Vertically integrated operations — where one entity holds multiple license types — file a separate registration for each activity type. And a separate application is required for each physical location.

If you hold an OMMA license and intend to continue operating, you need to register.

Several categories are outside the lane.

Recreational-only operators — no rec program in Oklahoma so this one is moot here, but worth knowing nationally. Hemp businesses operate under a separate federal framework entirely. Operators handling synthetically derived THC. Operators without a current, active OMMA license. And anyone whose OMMA license has been suspended or revoked — if the state license is gone, there's nothing to anchor the federal registration to.

The pathway is specifically for active state-licensed medical operators. If the OMMA license isn't current, the pathway isn't open.

June 27, 2026. That's 60 days from the Federal Register publication date of April 28.

For practical purposes, treat June 26 as your deadline. That's the last business day before the cutoff. Filing on June 27 is technically within the window, but leave yourself a business day of buffer — the portal has already seen heavy traffic.

Some early coverage cited June 22. That date was wrong. The publication date was April 28; the correct deadline is June 27.

Two things you get inside the window that disappear after June 27.

First, a processing target. The DEA Administrator must make every effort to decide your application within six months. File by June 27 and you have that commitment. File later and there's no timeline at all — standard DEA registration processing has historically run anywhere from a few months to well over a year.

Second, and more important: the right to keep operating under your OMMA license while your federal application is pending. File inside the window and you're protected. The federal rule explicitly authorizes continued manufacture, distribution, and dispensing under your state license during the review. File outside the window and that protection doesn't apply. During the review period, you'd be handling a Schedule III substance without federal authorization.

Same application. Same pathway. Materially different situation depending on which side of June 27 you're on.

Three layers of better.

The window. Filing by June 27 gets you a six-month processing target and the right to keep operating under your OMMA license while the federal application is reviewed. Those two protections go away after the window closes.

What the registration itself does. Once registered, you have federal-law authorization to handle a Schedule III substance. The DEA must grant it unless there's a specific public-interest problem with your application. You use your existing OMMA-compliant SOPs, security, and recordkeeping to satisfy most federal requirements — you're not double-regulated, you're regulated once with federal recognition layered on.

What it opens downstream. Banking and payment relationships that require Schedule III compliance treat DEA registration as the entry ticket. Any commerce between federally registered businesses — research arrangements, supply-chain transactions, whatever federal frameworks emerge from here — requires registration as the baseline. Every federal benefit of Schedule III flows through this registration.

One thing registration doesn't control: 280E relief. That flows from the rescheduling itself, not from registration. Don't mix the two up.

Nobody comes to shut you down. The federal government has been clear that the registration process isn't intended as an enforcement net for state-licensed operators. Your OMMA license still works. Patients still come. Day to day, things look the same.

But quietly, you fall behind.

Banking and payment relationships that open up for registered Schedule III operators don't open for you. Any chain of commerce that requires registrant-to-registrant documentation is closed off. Federal frameworks built on registration as the baseline — whatever Congress, Treasury, or DEA build next — won't include you. And the operators next to you who did register are moving into territory you're locked out of.

And if you change your mind later? You can still apply. But the window closed June 27, so you lose the six-month processing target and the right to keep operating while you wait for an answer.

The honest summary: not registering is survivable. It's also, under the new regime, the strictly worse position. The cost is paid in slow compounding losses, not in a single dramatic event.

Technically optional. Practically, it's the wrong frame.

The federal rule doesn't force you to register. Nobody will fine you on June 28 for not having filed. But every federal benefit the rescheduling created — banking access, federal operating authorization, federal commerce relationships, whatever frameworks develop from here — requires registration. Calling it "optional" is technically accurate in the same way it's technically optional to show up for your OMMA renewal.

For any medical operator planning to be in business in 2027 and beyond, the meaningful choice isn't file or don't. It's file now with the window open, or file later without the protections.

Yes, but the bar is high and the presumption runs in your favor.

The rule says the Administrator must grant the registration unless doing so would be inconsistent with the public interest or with U.S. treaty obligations. That's a must-grant standard with narrow exceptions — not discretionary approval.

The public-interest factors the DEA looks at are things like: prior DEA history, compliance record, diversion controls, criminal history of principals. For an OMMA-licensed dispensary or processor that's been in good standing, those factors point toward approval.

Refusals will happen, but they'll be based on specific concerns about a specific applicant — not blanket discretion to turn away state-licensed operators.

It means the default answer is yes, and the DEA has to have a real reason to say no.

Most federal approvals work the other way: the applicant has to prove they deserve it. This one flips that. The rule puts the burden on the agency. If the DEA wants to deny your application, it has to point to something specific — a compliance problem, a criminal history, a diversion risk — and explain why that specific thing makes approval inconsistent with the public interest.

For an operator that's been running clean under an OMMA license, "inconsistent with the public interest" is a difficult standard for the DEA to meet. That's by design.

Two different forms for two different roles.

Form 224 is for dispensers — the retail side, selling to qualifying patients. If you hold an OMMA dispensary license, this is your form.

Form 225 is for manufacturers and distributors. That covers growers, processors, and transporters.

If your operation is vertically integrated — say you grow, process, and dispense — you file both. One 225 for the upstream activities, one 224 for the dispensing side. Same legal entity, two separate registrations.

Both location and activity type. Each physical address gets its own application. Each activity type (grower, processor, transporter, dispenser) gets its own registration.

Same legal entity, multiple registrations. A single OMMA licensee with a grow site, a processing facility, and three dispensary locations files five separate applications — one for the grow, one for processing, three for the dispensaries.

The registration scope at each location can't go beyond what the OMMA license at that location allows.

Inside the window: the DEA must make every effort to decide within six months. Applications filed by June 27 are targeting decisions by approximately late October or early November 2026.

Outside the window: no timeline. Standard DEA processing has historically ranged from a few months to well over a year. There's no commitment, no queue priority, and no during-pendency operating protection while you wait.

Yes — if you filed inside the window.

The rule explicitly authorizes continued operation under your OMMA license during the review of your federal application, for operators who filed by June 27. You're covered. Keep running.

If you file after the window closes, that protection doesn't apply. Operating during the review period of a late-filed application means handling Schedule III cannabis without a federal registration — which is federally unauthorized handling of a controlled substance. The legal gap is real even if enforcement is unlikely.

The federal registration automatically suspends the moment the state license is suspended, revoked, or expires. There's no grace period. The federal authorization goes away when the state authorization goes away.

Reinstatement of the federal registration follows reinstatement of the OMMA license, but it's not automatic — there's a notification process to go through.

The practical implication: your OMMA renewal calendar needs to be on the radar before your federal renewal calendar. State first, always. A lapsed OMMA license is the fastest way to lose the federal registration.

Depends on your activity type.

Dispensaries renew every three years. Manufacturers and distributors renew annually. Renewal cycles run from the date your registration is granted, not the date you applied.

Factor this into your compliance calendar alongside the OMMA renewal schedule. The two run on different timelines and both need to stay current.

Application fee: $794 per location, paid at filing. Covers every activity type at that location.

Renewal fees: manufacturers pay approximately $3,699 per year; distributors approximately $1,850 per year; dispensaries approximately $888 per three-year cycle — roughly $296 per year equivalent.

Payment at filing is currently processed through PayPal. Additional payment methods are reportedly being added. Confirm current fee amounts on the DEA Diversion Control fee schedule before filing — the numbers are subject to periodic adjustment and these figures reflect the schedule as of mid-May 2026.